Company news: Novo Nordisk

Share this article:
Novo Nordisk reported first-half gains in operating profit of 13%, along with sales growth of 11% in local currencies driven by Victoza, NovoRapid and Levemir. Victoza sales were up 253% to around $444 million while sales of modern insulins were up 10% and North American sales rose 15%.

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.